Yumanity Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate Developments
BOSTON, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics, Inc. (“Yumanity” or the “Company”) (Nasdaq: YMTX), a clinical-stage biopharmaceutical...
INVESTIGATION NOTICE: Halper Sadeh LLP Investigates TPTX, DRE, CVET, YMTX
/PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
YUMANITY THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Yumanity Therapeutics, Inc. - YMTX
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating Yumanity Therapeutics, Inc. (NasdaqCM: YMTX) (the “Company”)...